A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

This study is testing a new medicine for adults with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. "Relapsed" means the cancer came back after treatment, and "refractory" means it didn't respond to treatment. The medicine stops a protein called MMSET from changing another protein, H3K36, which might help the cancer grow. The study has two parts. In Part A, researchers will find the safest dose by giving it to patients for 28 days and checking for side effects. In Part B, they'll give the safest dose to more patients to see how well it works.

• 🕐 Study involves taking medicine daily; initial safety check lasts 28 days.
• 💉 Participants must have tried at least three different treatments before.
• 🧪 Patients need specific tests to check for certain genetic markers.

Participants must be 18 or older and have tried other treatments without success. They can't join if they've recently had other cancer treatments or have certain health issues. This study might help find a new treatment option for RRMM patients.